Lab study explores how JAK inhibitors affect immune cells in arthritis

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion criteria: * General criteria * Patient, of 18 and more years old * Subject affiliated to a social security system * Subject not being in period of exclusion with regard to another protocol * Absence of pregnancy in the inclusion (date of the last period, use of a contraceptive method, ß -HCG impulsive person in case of doubt) * Informed consent * Criteria of inclusion of the group rheumatoid arthritis (in vitro studies): * Rheumatoid arthritis, corresponding to the the classification ACR / EULAR 2010 criteria * Criteria of inclusion of the group arthritis (in vitro studies): * Spinal degenerative osteoarthritis or degenerative osteoarthritis of the members, according to the clinical and radiological elements. * Criteria of inclusion of the group rheumatoid arthritis, longitudinal study at the patients treated by JAK / STAT inhibitors : * Rheumatoid Polyarthritis, corresponding to the classification ACR / EULAR 2010 criteria * Patient to whom a treatment by inhibitor of the way JAK / STAT was proposed in current care of rheumatoid arthritis. Exclusion criteria: * General criteria * Corticosteroid therapy superior to 10 mg / j * Drip of corticoids in the previous month * Pregnant or breast-feeding Patients * Patient under protection(saving) of justice * Under guardianship Patient or guardianship * Current Infection * Criteria of non-inclusion of the group rheumatoid polyarthritis ( in vitro studies): * Treatment by immunomodulateur or biotherapics (anti-TNF alpha, tocilizumab, abatacept or rituximab) in the previous year * Criteria of non-inclusion of the group arthritis ( in vitro studies): * History of autoimmune disease or néoplasie * Treatment by immunomodulateur or biotherapics (anti-TNF alpha, tocilizumab, abatacept or rituximab) * Criteria of non-inclusion of the group rheumatoid arthritis, longitudinal study at the patients treated by JAK / STAT inhibitors : Treatment by rituximab in the previous year